New markers may spot ovarian cancer earlier
NCT ID NCT02326064
First seen Jan 06, 2026 · Last updated Jun 10, 2026 · Updated 24 times
Summary
This study looked at whether adding a new tumor marker (HE4) and using special scoring systems (ROMA and RMI) can better tell the difference between harmless ovarian cysts and ovarian cancer. Researchers measured CA125 and HE4 levels in 221 women scheduled for ovarian cyst surgery. The goal was to improve early diagnosis and reduce uncertainty.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH de Saint Nazaire
Saint-Nazaire, 44606, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHU de Nantes
Nantes, 44093, France
-
Centre Hospitalier de Cholet
Cholet, 49300, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.